Cannabinoid pathways linked to bone cancer progression in children

This study investigates how lipid mediators called oxylipins—derived from fatty acids in the body—relate to pediatric bone cancers like osteosarcoma and Ewing sarcoma. Researchers analyzed blood samples from 52 young sarcoma patients and 20 healthy controls, discovering that cancer patients had dramatically different oxylipin profiles, with particularly elevated levels of linoleic acid metabolites (9-HODE, 9-HpODE, 13-KODE) in patients with advanced, metastatic disease. By examining gene expression patterns alongside these lipid profiles, the team identified key metabolic pathways that are disrupted in sarcomas.

Notably, the research identified dysregulation of genes involved in both oxylipin and cannabinoid metabolism, including the genes FAAH and CNR1—which are critical for processing endocannabinoids in the body. The dysregulation of FAAH (which breaks down the natural cannabinoid anandamide) and CNR1 (the cannabinoid receptor) suggests that the body's natural endocannabinoid system may be altered in these cancers, though the study doesn't explore therapeutic applications. The researchers created a 21-gene signature model that predicted patient survival with 91% accuracy, successfully distinguishing high-risk from low-risk osteosarcoma patients across multiple datasets. These findings suggest that oxylipin pathways and related metabolic systems—including cannabinoid metabolism—could become targets for developing new diagnostic tools and treatments for pediatric bone cancers.

This research opens new doors for understanding how the body's own lipid signaling systems, including endocannabinoid metabolism, may influence cancer progression. While not directly testing cannabinoid treatments, the identification of cannabinoid gene dysregulation in sarcomas raises intriguing questions about whether modulating these pathways could become part of future cancer therapies.